Read about the safety information of LUCENTIS
LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), and diabetic macular edema (DME).
LUCENTIS is a prescription medication given by injection into the eye, and it has side effects. Some LUCENTIS patients have had detached retinas and serious infections inside the eye. You should not use LUCENTIS if you have an infection in or around the eye or are allergic to LUCENTIS or any of its ingredients.
Uncommonly, LUCENTIS patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes.
Some patients have had increased eye pressure before and within 1 hour of an injection.
Serious side effects include inflammation inside the eye and, rarely, problems related to the injection procedure, such as cataracts. These side effects can make your vision worse.
The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non-eye-related side effects are nose and throat infections, headache, lung/airway infections, and nausea.
If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away.
For additional safety information, please talk to your doctor and see the LUCENTIS full prescribing information.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech, Inc. does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
Wet age-related macular degeneration(wet AMD)
Macular edema following retinal vein occlusion(RVO)
LUCENTIS is supported by 3 years of clinical research in DME
LUCENTIS was studied in 502 patients, in 2 clinical trials lasting 3 years each. In 2012, LUCENTIS was FDA-approved to treat DME.
In 2 clinical trials, some patients given LUCENTIS could read additional letters as early as 7 days after their first treatment.
Not all patients on LUCENTIS experienced this result. Individual results may vary.
Possible serious side effects of LUCENTIS
Some patients gained 15 letters or more
In 2 clinical studies lasting 3 years, 4 out of 10 patients receiving LUCENTIS each month gained 15 letters or more on an eye chart compared with 2 out of 10 patients not receiving LUCENTIS.
A person with DME may be able to read only a few letters on the eye chart.
Someone receiving LUCENTIS may be able to see an additional 15 letters.*
* Individual results may vary.
In these studies, patients continued to receive LUCENTIS treatment over a 3-year period. Some of these patients saw significant improvement throughout their first year and some patients lost letters. Of patients who gained letters, some kept those gains throughout the second and third year.
What does it mean to see 15 more letters?
Your Retina Specialist uses an eye chart to measure your vision. The farther down the chart you can see— as the letters get smaller—the better your vision.
What is visual acuity?
You've probably heard of 20/20 vision. That's a measure of visual acuity, and 20/20 is normal vision. A person with 20/20 vision can stand 20 feet from something and see it clearly.
20/40 is also a good score. People with 20/40 vision usually do not have trouble with reading, seeing small letters, or watching sporting events.
In 2 clinical studies lasting 3 years, 6 out of 10 patients receiving LUCENTIS maintained* their visual acuity score or improved it to 20/40 or better. This means they were able to see details more clearly.
With LUCENTIS, you could improve your visual acuity. In fact, LUCENTIS is the first and only FDA-approved medicine shown to improve vision in people with DME.
Partner with your Retina Specialist and get LUCENTIS treatments as recommended.
*Defined as losing fewer than 15 letters.
LUCENTIS is a medicine that is injected by your doctor into the eye. Like all medicines, LUCENTIS has possible side effects. It is important for you to know what they are.
Talk with your eye doctor if you have:
Although it is uncommon, some people treated with LUCENTIS may have a life-threatening side effect.
Your doctor will stop treatment if any serious side effects occur. Be sure to contact your doctor if there are any signs of side effects.
Serious reactions have occurred related to the injection. They have happened in fewer than 0.1% (1 in 1,000) of people. These reactions can make your vision worse.
The retina is the light-sensitive layer of tissue that lines the inside of the eye. It sends visual messages through the optic nerve to the brain. When the retina detaches, it is lifted or pulled from its normal position.
A cataract is a clouding of the lens of the eye.
Some people have increased eye pressure before and within 1 hour after an injection. Your eye doctor should check your eyes and your eye pressure during the week after your injection.
A stroke happens when a blood vessel that carries oxygen to the brain is either blocked by a clot or bursts. This means that part of the brain cannot get the oxygen it needs. As a result, the brain gets damaged.
A heart attack happens when a blood vessel that carries oxygen to the heart is either blocked by a clot or bursts. This means that part of the heart cannot get the oxygen it needs. As a result, the heart gets damaged.
Call or visit your eye doctor right away if:
Here are the most common eye-related side effects in clinical studies of LUCENTIS:
Here are the most common non-eye-related side effects in clinical studies of LUCENTIS:
LUCENTIS is for prescription use only.